Orlando, FL 的 乳癌 臨床試驗
23 項針對 乳癌 的研究正在 Orlando（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- AdventHealth, Altamonte Springs · 距離 9 英里
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Advent Health, Orlando
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 距離 16 英里
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024), Altamonte Springs · 距離 9 英里
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- Orlando Health Cancer Institute ( Site 0011), Orlando
- AdventHealth Altamonte Springs ( Site 0021), Altamonte Springs · 距離 9 英里
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Altamonte Springs · 距離 9 英里
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044), Altamonte Springs · 距離 9 英里
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- AdventHealth Altamonte Springs, Altamonte Springs · 距離 9 英里
- Clermont Oncology Center, Clermont · 距離 24 英里
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
招募中2 期
- AdventHealth Altamonte Springs, Altamonte Springs · 距離 9 英里
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
招募中1/2 期
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- AdventHealth Orlando Infusion Center, Orlando
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
招募中1 期
- Cancer Centers of Florida, Ocoee · 距離 10 英里
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- Advent Health - Orlando, Orlando
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · 距離 9 英里
- 還有 1 項
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · 距離 9 英里
- 還有 1 項
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Florida Cancer Specialists, Orlando
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
招募中觀察性研究
- AdventHealth East Altamonte Oncology and Hematology, Altamonte Springs · 距離 9 英里
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
招募中觀察性研究歡迎健康志工
- Adventhealth, Orlando
UCF MammoChat: Image Repository
招募中觀察性研究歡迎健康志工
- University of Central Florida, Orlando
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- Florida Cancer Specialists, Orlando
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
招募中1 期
- Exelixis Clinical Site #8, Orlando
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Orlando 的其他研究
- 非小細胞肺癌44 項研究
- 肥胖症32 項研究
- 轉移性癌症29 項研究
- 過重27 項研究
- 阿茲海默症25 項研究
- 第二型糖尿病25 項研究
- 癌症（所有類型）24 項研究
- 卵巢癌22 項研究
- 潰瘍性結腸炎22 項研究
- 肺癌21 項研究
- 大腸直腸癌19 項研究
- 重度憂鬱症19 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。